Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02615171 · ClinicalTrials.gov registry record · NA
RELAX: A Mobile Application Suite Targeting Obesity and Stress
A NA study, sponsored by University of Connecticut.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT02615171: Completed NA study, sponsored by University of Connecticut.
NCT02615171 is a NA study that has completed, run by University of Connecticut. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02615171, a NA study, has completed, sponsored by University of Connecticut.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This research is being done is to evaluate the feasibility and acceptability of a novel weight loss mobile app that was designed to be less burdensome than traditional weight loss apps.
Primary Outcome
App use was measured for each condition using either backend data from Slip Buddy or reviewing MyFitnessPal entries indicating use over each 24-hour period.
Interventions
- BEHAVIORAL Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity
- BEHAVIORAL Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2019-11-30 |
| Phase | NA |
What the finished NCT02615171 record still lists
NCT02615171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity is the first listed.
NCT02615171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02615171 about?
NCT02615171 is a clinical study titled "RELAX: A Mobile Application Suite Targeting Obesity and Stress". This research is being done is to evaluate the feasibility and acceptability of a novel weight loss mobile app that was designed to be less burdensome than traditional weight loss apps.
What is the current status of trial NCT02615171?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2019-07-08. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT02615171?
The interventions under investigation include: Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity (BEHAVIORAL), Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity (BEHAVIORAL).
Who is sponsoring clinical trial NCT02615171?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02615171's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI